scholarly journals Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)

2017 ◽  
Vol 5 (2) ◽  
pp. 54-59
Author(s):  
Ebrahim Abbasi Oshaghi
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Receptor Agonist ◽  
Alcoholic Fatty Liver ◽  
Dipeptidyl Peptidase 4 ◽  
New Finding ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-1 (GLP-1) is a significant regulator of energy balance, show potential efficacy in the management of NAFLD. GLP-1 and GLP-1 receptor agonist (GLP-1RAs) are attractive options for the treatment of type 2 diabetes (T2D) since they efficiently reduce weight, HbA1C and blood glucose without having a risk of hypoglycaemia. This incretin hormone by normalizing of insulin resistance (IR), oxidative stress, lipid accumulation, lipotoxicity, and liver cell apoptosis is proposed for the management of NAFLD and nonalcoholic steatohepatitis (NASH) patient. Hence, the aim of this review was to discuss the useful effects of GLP-1, GLP-1 receptor agonist (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) on NAFLD. In this paper we provided a new finding which highlighted the role of GLP-1 and GLP-1RAs in the treatment of NAFLD.

scholarly journals Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e87488 ◽  
Author(s):  
Christine Bernsmeier ◽  
Anne C. Meyer-Gerspach ◽  
Lea S. Blaser ◽  
Lia Jeker ◽  
Robert E. Steinert ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease

2016 ◽  
Vol 64 (4) ◽  
pp. 908-915 ◽  
Author(s):  
Anders E. Junker ◽  
Lise L. Gluud ◽  
Gerrit van Hall ◽  
Jens J. Holst ◽  
Filip K. Knop ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Glucagon Secretion ◽  
Alcoholic Fatty Liver ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

scholarly journals Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Chloe Wong ◽  
Ming Hui Lee ◽  
Clyve Yu Leon Yaow ◽  
Yip Han Chin ◽  
Xin Lei Goh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Alcoholic Fatty Liver Disease

ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite this, there has been limited evidence of its efficacy in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. This meta-analysis examined existing evidence on the efficacy of glucagon-like peptide-1 receptor agonists on the management of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.MethodsMedline, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for articles discussing the efficacy of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Values of standardized mean differences (SMD) and risk ratio (RR) were determined for continuous outcomes and dichotomous outcomes respectively.Results8 studies involving 1,454 patients from 5 randomized controlled trials and 3 cohort studies were included in the analysis. Our analysis found significant improvements in hepatic fat content, liver biochemistry, body composition, glucose parameters, lipid parameters, insulin sensitivity and inflammatory markers following glucagon-like peptide-1 receptor agonist treatment. Glucagon-like peptide-1 receptor agonists significantly decreased hepatic fat content compared to metformin and insulin-based therapies. Glucagon-like peptide-1 receptor agonists also improved fibrosis markers, but this did not reach statistical significance.ConclusionWith a high prevalence of obesity and non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonist treatment shows promise in improving both diabetes and non-alcoholic fatty liver disease phenotype.

Sign in / Sign up

Export Citation Format

Share Document